litlas
Log inCreate account

Satoshi Morita

Active 2000–2026

219
Papers
30,737
Citations
88
h-index
191
i10-index

Citations

Citations per year for Satoshi Morita1996: 1 citations1997: 1 citations2000: 1 citations2001: 6 citations2002: 10 citations2003: 2 citations2004: 2 citations2005: 4 citations2006: 5 citations2007: 12 citations2008: 25 citations2009: 28 citations2010: 89 citations2011: 214 citations2012: 207 citations2013: 281 citations2014: 238 citations2015: 323 citations2016: 280 citations2017: 307 citations2018: 287 citations2019: 1,064 citations2020: 1,089 citations2021: 1,133 citations2022: 774 citations2023: 539 citations2024: 920 citations2025: 440 citations2026: 21 citations1998–1999: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,061 citing papers, 19% of this breakdownChina: 1,681 citing papers, 15.5% of this breakdownJapan: 1,494 citing papers, 13.8% of this breakdownItaly: 505 citing papers, 4.7% of this breakdownUnited Kingdom: 500 citing papers, 4.6% of this breakdownSouth Korea: 405 citing papers, 3.7% of this breakdownGermany: 387 citing papers, 3.6% of this breakdownFrance: 361 citing papers, 3.3% of this breakdownSpain: 291 citing papers, 2.7% of this breakdownCanada: 276 citing papers, 2.5% of this breakdownTaiwan: 232 citing papers, 2.1% of this breakdownNetherlands: 230 citing papers, 2.1% of this breakdown
0%19%Other 22.4%

Institutions

Fields

  • Medicine71.8%
  • Biochemistry, Genetics and Molecular Biology14.3%
  • Computer Science3.5%
  • Immunology and Microbiology2.6%
  • Engineering1.5%
  • Agricultural and Biological Sciences1%
  • Other5.3%

Topics

  • Lung Cancer Treatments and Mutations9.3%
  • Cancer Immunotherapy and Biomarkers4.1%
  • Lung Cancer Diagnosis and Treatment3.9%
  • Lung Cancer Research Studies3.8%
  • Colorectal Cancer Treatments and Studies2.3%
  • Gastric Cancer Management and Outcomes2.3%
  • Other74.3%

Coauthors

All papers

Open in search
  1. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

    Authors: Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi, Shunichi Sugawara, Satoshi Oizumi, Hiroshi Isobe, Akihiko Gemma, Masao Harada, Hirohisa Yoshizawa, Ichiro Kinoshita, Yuka Fujita, Shoji Okinaga, Haruto Hirano, Kozo Yoshimori, Toshiyuki Harada, Takashi Ogura, Masahiro Ando, Hitoshi Miyazawa, Tomoaki Tanaka, Yasuo Saijo, Koichi Hagiwara, Satoshi Morita, Toshihiro Nukiwa - New England Journal of Medicine 2010 cited by 5,571

  2. Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

    Authors: Junzo Hamanishi, Masaki Mandai, Takafumi Ikeda, Manabu Minami, Atsushi Kawaguchi, Toshinori Murayama, Masashi Kanai, Yukiko Mori, Shigemi Matsumoto, Shunsuke Chikuma, Noriomi Matsumura, Kaoru Abiko, Tsukasa Baba, Ken Yamaguchi, Akihiko Ueda, Yuko Hosoe, Satoshi Morita, Masayuki Yokode, Akira Shimizu, Tasuku Honjo, Ikuo Konishi - Journal of Clinical Oncology 2015 cited by 1,192

  3. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

    Authors: Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe, Shunichi Negoro, Isamu Okamoto, Junji Tsurutani, Takashi Seto, Miyako Satouchi, Hirohito Tada, Tomonori Hirashima, Kazuhiro Asami, Nobuyuki Katakami, Minoru Takada, Hiroshige Yoshioka, Kazuhiko Shibata, Shinzoh Kudoh, Eiji Shimizu, Hiroshi Saito, Shinichi Toyooka, Kazuhiko Nakagawa, Masahiro Fukuoka - The Lancet Oncology 2009 cited by 4,114

  4. Mathematical foundation of quantum annealing

    Authors: Satoshi Morita, Hidetoshi Nishimori - Journal of Mathematical Physics 2008 cited by 385

  5. Human iPS cell-derived dopaminergic neurons function in a primate Parkinson’s disease model

    Authors: Tetsuhiro Kikuchi, Asuka Morizane, Daisuke Doi, Hiroaki Magotani, Hirotaka Onoe, Takuya Hayashi, Hiroshi Mizuma, Sayuki Takara, Ryōsuke Takahashi, Haruhisa Inoue, Satoshi Morita, Michio Yamamoto, Keisuke Okita, Masato Nakagawa, Malin Parmar, Jun Takahashi - Nature 2017 cited by 700

  6. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study

    Authors: Yukio Hosomi, Satoshi Morita, Shunichi Sugawara, Terufumi Kato, Tatsuro Fukuhara, Akihiko Gemma, Kazuhisa Takahashi, Yuka Fujita, Toshiyuki Harada, Koichi Minato, Kei Takamura, Koichi Hagiwara, Kunihiko Kobayashi, Toshihiro Nukiwa, Akira Inoue, for the North-East Japan Study Group - Journal of Clinical Oncology 2019 cited by 483

  7. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

    Authors: Haruhiro Saito, Tatsuro Fukuhara, Naoki Furuya, Kana Watanabe, Shunichi Sugawara, Shunichiro Iwasawa, Yoshio Tsunezuka, Ou Yamaguchi, Morihito Okada, Kozo Yoshimori, Ichiro Nakachi, Akihiko Gemma, Koichi Azuma, Futoshi Kurimoto, Yukari Tsubata, Yuka Fujita, Hiromi Nagashima, Gyo Asai, Satoshi Watanabe, Masaki Miyazaki, Koichi Hagiwara, Toshihiro Nukiwa, Satoshi Morita, Kunihiko Kobayashi, Makoto Maemondo - The Lancet Oncology 2019 cited by 636

  8. Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR

    Authors: Eisaku Miyauchi, Satoshi Morita, Atsushi Nakamura, Yukio Hosomi, Kana Watanabe, Satoshi Ikeda, Masahiro Seike, Yuka Fujita, Koichi Minato, Ryo Ko, Toshiyuki Harada, Koichi Hagiwara, Kunihiko Kobayashi, Toshihiro Nukiwa, Akira Inoue, for the North-East Japan Study Group - Journal of Clinical Oncology 2022 cited by 90

  9. Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial

    Authors: Shuichi Hironaka, Shinya Ueda, Hirofumi Yasui, Tomohiro Nishina, Masahiro Tsuda, Takehiko Tsumura, Naotoshi Sugimoto, Hideki Shimodaira, Shinya Tokunaga, Toshikazu Moriwaki, Taito Esaki, Michitaka Nagase, Kazumasa Fujitani, Kensei Yamaguchi, Takashi Ura, Yasuo Hamamoto, Satoshi Morita, Isamu Okamoto, Narikazu Boku, Ichinosuke Hyodo - Journal of Clinical Oncology 2013 cited by 559

  10. Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

    Authors: Masatoshi Kudo, Ann‐Lii Cheng, Joong‐Won Park, Jae Hyung Park, Po‐Chin Liang, Hisashi Hidaka, Namiki Izumi, Jeong Heo, Youn Jae Lee, I‐Shyan Sheen, Chang‐Fang Chiu, Hitoshi Arioka, Satoshi Morita, Yasuaki Arai - ˜The œLancet. Gastroenterology & hepatology 2017 cited by 196

  11. International Retrospective Cohort Study of Conversion Therapy for Stage IV Gastric Cancer 1 (CONVO‐GC‐1)

    Authors: Kazuhiro Yoshida, Itaru Yasufuku, Masanori Terashima, Sun Young Rha, Jae Moon Bae, Guoxin Li, Hitoshi Katai, Masahiko Watanabe, Yasuyuki Seto, Sung Hoon Noh, Han Kwang Yang, Jiafu Ji, Hideo Baba, Yuko Kitagawa, Satoshi Morita, Masahiko Nishiyama, Yasuhiro Kodera - Annals of Gastroenterological Surgery 2021 cited by 157

  12. Regnase-1 Prevents Pulmonary Arterial Hypertension Through mRNA Degradation of Interleukin-6 and Platelet-Derived Growth Factor in Alveolar Macrophages

    Authors: Ai Yaku, Tadakatsu Inagaki, Ryotaro Asano, Makoto Okazawa, Hiroyoshi Mori, Ayuko Sato, Fabian Hia, Takeshi Masaki, Yusuke Manabe, Tomohiko Ishibashi, Alexis Vandenbon, Yoshinari Nakatsuka, Kotaro Akaki, Masanori Yoshinaga, Takuya Uehata, Takashi Mino, Satoshi Morita, Hatsue Ishibashi‐Ueda, Akio Morinobu, Tohru Tsujimura, Takeshi Ogo, Yoshikazu Nakaoka, Osamu Takeuchi - Circulation 2022 cited by 73

  13. Epigenetic mechanisms to propagate histone acetylation by p300/CBP

    Authors: Masaki Kikuchi, Satoshi Morita, Masatoshi Wakamori, Shin Sato, Tomomi Uchikubo‐Kamo, Takehiro Suzuki, Naoshi Dohmae, Mikako Shirouzu, Takashi Umehara - Nature Communications 2023 cited by 66

  14. Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial

    Authors: Yosuke Kawashima, Tatsuro Fukuhara, Haruhiro Saito, Naoki Furuya, Kana Watanabe, Shunichi Sugawara, Shunichiro Iwasawa, Yoshio Tsunezuka, Ou Yamaguchi, Morihito Okada, Kozo Yoshimori, Ichiro Nakachi, Masahiro Seike, Koichi Azuma, Futoshi Kurimoto, Yukari Tsubata, Yuka Fujita, Hiromi Nagashima, Gyo Asai, Satoshi Watanabe, Masaki Miyazaki, Koichi Hagiwara, Toshihiro Nukiwa, Satoshi Morita, Kunihiko Kobayashi, Makoto Maemondo - The Lancet Respiratory Medicine 2021 cited by 125

  15. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor

    Authors: Hiroaki Akamatsu, Yukihiro Toi, Hidetoshi Hayashi, Daichi Fujimoto, Motoko Tachihara, Naoki Furuya, Sakiko Otani, Junichi Shimizu, Nobuyuki Katakami, Koichi Azuma, Naoko Miura, Kazumi Nishino, Satoshi Hara, Shunsuke Teraoka, Satoshi Morita, Kazuhiko Nakagawa, Nobuyuki Yamamoto - JAMA Oncology 2021 cited by 185

  16. Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC

    Authors: Yasuto Yoneshima, Satoshi Morita, Masahiko Ando, Atsushi Nakamura, Shunichiro Iwasawa, Hiroshige Yoshioka, Yasuhiro Gotô, Masafumi Takeshita, Toshiyuki Harada, Katsuya Hirano, Tetsuya Oguri, Masashi Kondo, Satoru Miura, Yukio Hosomi, Terufumi Kato, Toshio Kubo, Junji Kishimoto, Nobuyuki Yamamoto, Yoichi Nakanishi, Isamu Okamoto - Journal of Thoracic Oncology 2021 cited by 106

  17. Impaired CD4+ T cell response in older adults is associated with reduced immunogenicity and reactogenicity of mRNA COVID-19 vaccination

    Authors: Norihide Jo, Yu Hidaka, Osamu Kikuchi, Masaru Fukahori, Takeshi Sawada, Masahiko Aoki, Masaki Yamamoto, Miki Nagao, Satoshi Morita, Takako Eguchi Nakajima, Manabu Muto, Yoko Hamazaki - Nature Aging 2023 cited by 79

  18. 2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease

    Authors: Hiroyasu Yamamoto, Shinichi Nishi, Tadashi Tomo, Ikuto Masakane, Kazuhide Saito, Masaomi Nangaku, Motoshi Hattori, Takahiro Suzuki, Satoshi Morita, Akira Ashida, Yasuhiko Ito, Takahiro Kuragano, Yasuhiro Komatsu, Ken Sakai, Yoshiharu Tsubakihara, Kazuhiko Tsuruya, Terumasa Hayashi, Hideki Hirakata, Hirokazu Honda - Renal Replacement Therapy 2017 cited by 245

  19. Prevalence and factors associated with sarcopenia in patients with rheumatoid arthritis

    Authors: Mie Torii, Motomu Hashimoto, Akiko Hanai, Takao Fujii, Moritoshi Furu, Hiromu Ito, Ryuji Uozumi, Masahide Hamaguchi, Chikashi Terao, Wataru Yamamoto, Miyabi Uda, Kazuko Nin, Satoshi Morita, Hidenori Arai, Tsuneyo Mimori - Modern Rheumatology 2018 cited by 170

  20. Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson’s disease

    Authors: Nobukatsu Sawamoto, Daisuke Doi, Etsuro Nakanishi, Masanori Sawamura, Takayuki Kikuchi, Hodaka Yamakado, Yosuke Taruno, Atsushi Shima, Yasutaka Fushimi, Tomohisa Okada, Tetsuhiro Kikuchi, Asuka Morizane, Satoe Hiramatsu, Takayuki Anazawa, Takero Shindo, Kentaro Ueno, Satoshi Morita, Yoshiki Arakawa, Yuji Nakamoto, Susumu Miyamoto, Ryōsuke Takahashi, Jun Takahashi - Nature 2025 cited by 142

  21. Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease

    Authors: Satoko Miyatake, Noriko Miyake, Hajime Touho, A. Nishimura-Tadaki, Yasuhiko Kondo, Ichiro Okada, Yoshinori Tsurusaki, Hiroshi Doi, H. Sakai, Hirotomo Saitsu, Keiko Shimojima, Tatsuya Yamamoto, Masakazu Higurashi, N. Kawahara, H. Kawauchi, Kenji Nagasaka, Nobuhiko Okamoto, Toshio Mori, Shigeru Koyano, Yoshifumi Kuroiwa, Masataka Taguri, Satoshi Morita, Yoichi Matsubara, Shigeo Kure, Naomichi Matsumoto - Neurology 2012 cited by 303

  22. Validation Study of the International Association for the Study of Lung Cancer Histologic Grading System of Invasive Lung Adenocarcinoma

    Authors: Mariyo Rokutan‐Kurata, Akihiko Yoshizawa, Kentaro Ueno, Naoki Nakajima, Kazuhiro Terada, Masatsugu Hamaji, Makoto Sonobe, Toshi Menju, Hiroshi Date, Satoshi Morita, Hironori Haga - Journal of Thoracic Oncology 2021 cited by 108

  23. Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial

    Authors: Keiko Imamura, Yuishin Izumi, Makiko Nagai, Kazutoshi Nishiyama, Yasuhiro Watanabe, Ritsuko Hanajima, Naohiro Egawa, Takashi Ayaki, Ryosuke Oki, Koji Fujita, Ryuji Uozumi, Akiko Morinaga, Tomoko Hirohashi, Yosuke Fujii, Takuya Yamamoto, Harutsugu Tatebe, Takahiko Tokuda, Naoto Takahashi, Satoshi Morita, Ryōsuke Takahashi, Haruhisa Inoue - EClinicalMedicine 2022 cited by 53

  24. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

    Authors: K. Yamazaki, Michitaka Nagase, H Tamagawa, Shinya Ueda, Takao Tamura, K. Murata, Takako Eguchi Nakajima, Eishi Baba, Masahiro Tsuda, Toshikazu Moriwaki, Taito Esaki, Yasushi Tsuji, Kei Muro, Koichi Taira, Tadamichi Denda, Sadao Funai, Katsunori Shinozaki, Hitoshi Yamashita, Naotoshi Sugimoto, Tatsuya Okuno, Tomohiro Nishina, M. Umeki, Takayuki Kurimoto, Tetsuji Takayama, Akihito Tsuji, Miki Yoshida, A. Hosokawa, Yoshihiro Shibata, Koichi Suyama, Masaru Okabe, Koichi Suzuki, Narihito Seki, Kentaro Kawakami, Mikio Sato, Koshi Fujikawa, T. Hirashima, Takaya Shimura, K. Taku, Toshio Otsuji, F. Tamura, Eiji Shinozaki, Kazutaka Nakashima, Hiroki Hara, Takahiro Tsushima, Masahiko Ando, Satoshi Morita, Narikazu Boku, Ichinosuke Hyodo - Annals of Oncology 2016 cited by 282